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Abstract
Background: Osteoprotegerin (OPG), a soluble member of the tumor necrosis factor receptor superfamily, is linked
to cardiovascular disease. Negative associations exist between circulating OPG and cardiac function. The
adipocytokine adiponectin (ADPN) is downregulated in type 2 diabetes mellitus (T2DM) and coronary artery disease
and shows an inverse correlation with insulin sensitivity and cardiovascular disease risk. We assessed the relationship
of plasma OPG and ADPN and arterial function, cardiac function and myocardial glucose metabolism in T2DM.
Methods: We included 78 asymptomatic men with uncomplicated, well-controlled T2DM, without inducible
ischemia, assessed by dobutamine-stress echocardiography, and 14 age-matched controls. Cardiac function was
measured by magnetic resonance imaging, myocardial glucose metabolism (MMRglu) by 18F-2-fluoro-2-deoxy-D-
glucose positron emission tomography. OPG and ADPN levels were measured in plasma.
Results: T2DM patients vs. controls showed lower aortic distensibility, left ventricular (LV) volumes, impaired LV
diastolic function and MMRglu (all P < 0.05). In T2DM men vs. controls, OPG levels were higher (P = 0.02), whereas
ADPN concentrations were decreased (P = 0.04). OPG correlated inversely with aortic distensibility, LV volumes and
E/A ratio (diastolic function), and positively with LV mass/volume ratio (all P < 0.05). Regression analyses showed
the associations with aortic distensibility and LV mass/volume ratio to be independent of age-, blood pressure- and
glycated hemoglobin (HbA1c). However, the associations with LV volumes and E/A ratio were dependent of these
parameters. ADPN correlated positively with MMRglu (P < 0.05), which, in multiple regression analysis, was
dependent of whole-body insulin sensitivity, HbA1c and waist.
Conclusions: OPG was inversely associated with aortic distensibility, LV volumes and LV diastolic function, while
ADPN was positively associated with MMRglu. These findings indicate that in asymptomatic men with
uncomplicated T2DM, OPG and ADPN may be markers of underlying mechanisms linking the diabetic state to
cardiac abnormalities.
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Background
Type 2 diabetes mellitus (T2DM) patients are at high
risk of developing cardiovascular disease [1]. Even in the
absence of hypertension and coronary artery disease, left
ventricular (LV) diastolic dysfunction occurs in a large
proportion of asymptomatic T2DM patients [2,3]. Iden-
tification of the individual risk is important for the pre-
vention and treatment of cardiovascular disease.
Appropriate biomarkers could be important for risk
stratification.
Osteoprotegerin (OPG) was first described as a key
factor in bone remodeling [4]. OPG is a member of
the tumor necrosis factor (TNF) receptor family, and a
decoy receptor for the receptor activator of nuclear
factor-B ligand (RANKL) and TNF-a related apopto-
sis-inducing ligand. It prevents RANKL from binding
to its receptor on osteoclasts, thereby inhibiting osteo-
clastogenesis [4]. Furthermore, OPG has been impli-
cated in human atherogenesis [5,6]. Previously, an
association between OPG and LV dysfunction in the
general population was described [7]. In addition, ele-
vated OPG levels were present in patients with heart
failure [8]. Recently, circulating OPG levels were
reported as independent predictor of cardiovascular
mortality in patients with stable coronary artery dis-
ease [9]. In asymptomatic T2DM patients OPG levels
predicted subclinical atherosclerosis and cardiovascular
events [10]. A 17-year prospective observational study
in T2DM patients showed a strong predictive value of
OPG for all-cause mortality, independent of conven-
tional risk for cardiovascular disease, including renal
function [11].
The adipocytokine adiponectin (ADPN) is downregu-
lated in T2DM [12]. This hypoadiponectinemia in
T2DM is associated with impaired insulin sensitivity,
and to a lesser extent with adiposity and glycemia [13].
Furthermore, lower adiponectin levels have been found
in T2DM patients with diabetic foot, a complication
characterized by neuropathy, microvascular defects and
inflammation compared to T2DM patients without dia-
betic foot [14]. Among men with T2DM, ADPN was
negatively associated with the risk of coronary artery
disease, which seemed to be partly mediated by high
density lipoprotein (HDL)-cholesterol, but independent
of other blood lipids, glycated hemoglobin (HbA1c), or
inflammatory markers [15].
The present study was based on the hypotheses that
circulating OPG and ADPN levels may differ between
asymptomatic men with uncomplicated T2DM and age
matched normoglycemic controls and that these bio-
markers may be associated with arterial function, cardiac
function and metabolism in these subjects.
Methods
Subjects
This cross-sectional study was a substudy of the pre-
viously published Pioglitazone Influence on tRiglyceride
Accumulation in the Myocardium in Diabetes (PIRA-
MID) study [2,16,17]. In short, 78 asymptomatic men
with well-controlled, uncomplicated T2DM, in whom
inducible ischemia was excluded by dobutamine-stress
echocardiography, and 14 age-matched healthy normo-
glycemic, as ascertained by an oral glucose tolerance
test, men were included. All T2DM patients received
glimepiride monotherapy. Inclusion criteria were HbA1c
6.5-8.5% at screening, body mass index [BMI; weight/
(lenght2)] 25-32 kg/m2 and blood pressure not exceed-
ing 150/85 mmHg. Exclusion criteria included known
cardiovascular disease, kidney disease, hepatic disease or
impaired hepatic function, diabetes related complica-
tions, including proliferative retinopathy; microalbumi-
nuria; autonomic neuropathy as assessed by Ewing’s
tests [18], current or previous use of thiazolidinediones,
incretin-based treatments and insulin, and contraindica-
tions for magnetic resonance imaging (MRI).
The protocol was approved by the Medical Ethics
Review Committee of the VU University Medical Center
and Leiden University Medical Center, and the study
was performed in full compliance with the Declaration
of Helsinki. All participants provided written informed
consent prior to inclusion.
Cardiac MRI protocol
MRI assessments were performed after an overnight fast
using a 1.5 Tesla whole-body MRI scanner (Gyroscan
ACS/NT15; Philips, Best, the Netherlands), described
previously [2,16,17,19]. Images were analyzed quantita-
tively using dedicated software (MASS and FLOW,
Medis, Leiden, the Netherlands).
A retrospective ECG-gated gradient-echo sequence
with velocity encoding was applied to measure through
plane flow at a predefined position at the mid ascending
aorta. Imaging parameters included the following: echo
time = 4.83 ms, repetition time = 14 ms, flip-angle =
20°, slice thickness = 8 mm, field of view = 350 mm,
matrix size = 256 × 256, velocity encoding gradient
(Venc) = 150 cm/s, scan percentage = 80%. The tem-
poral resolution was approximately 25 ms depending on
the heart rate. The in-plane spatial resolution was 1.37
× 1.76 mm after reconstruction.
Distensibility of the aorta derived from flow measure-
ments at the mid ascending aorta was calculated using
this formula:
D = (Amax − Amin)/(Amin × pulse pressure)
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Where D = distensibility (mmHg-1), Amax = maximal
aortic area (mm2), Amin = minimal aortic area (mm
2),
pulse pressure = systolic blood pressure-diastolic blood
pressure (mmHg) [20].
The entire heart was imaged in short-axis orientation
using ECG-gated breathholds with a sensitivity encoding
balanced turbo-field echo sequence. LV ejection fraction
was assessed for the determination of LV systolic func-
tion. In addition, LV mass/(enddiastolic) volume ratio
was calculated. Imaging parameters included the follow-
ing: echo time = 6 ms, repetition time = 11 ms, tem-
poral resolution = 35-39 ms per cardiac phase,
depending on the heart rate, flip-angle = 30°, slice thick-
ness = 10 mm, field of view = 400 mm, matrix size =
256 × 256. Furthermore, an ECG-gated gradient-echo
sequence with velocity encoding was performed to mea-
sure blood flow across the mitral valve for determina-
tion of LV diastolic parameters. Imaging parameters
included the following: echo time = 4.83 ms, repetition
time = 14 ms, flip-angle = 20°, slice thickness = 8 mm,
field of view = 350 mm, matrix size = 256 × 256, Venc
= 100 cm/s, scan percentage = 80%. The resulting
biphasic diastolic inflow pattern consists of 2 peaks,
representing the early filling phase and the atrial con-
traction. Analysis of the early filling phase and the atrial
contraction was performed by calculating their peak fill-
ing rates and ratio of the peak filling rates (E/A). In
addition, the peak deceleration gradient of the early fill-
ing phase (E deceleration peak) was calculated automati-
cally. An estimation of LV filling pressures (E/Ea) was
assessed [21]. During MRI, blood pressure and heart
rate were measured.
Positron Emission Tomography (PET) protocol
PET assessments were performed after an overnight fast
using an ECAT EXACT HR+ scanner (Siemens/CTI,
Knoxville, TN, USA). Myocardial blood flow was mea-
sured with H2
15O in the fasting state. After a 10-min-
utes transmission scan, 1100 MBq H2
15O was injected,
and a dynamic emission scan (40 frames) was acquired.
Myocardial metabolic rate of glucose (MMRglu) was
measured during an euglycemic-clamp procedure [22]
using [18F]-2-fluoro-2-deoxy-D-glucose (18FDG). A 60-
minutes dynamic emission scan (40 frames) was
acquired following injection of 185 MBq18FDG [17].
PET Image Analysis
PET data were quantitatively reconstructed with filtered
backprojection applying all appropriate corrections. To
generate myocardial time-activity curves, regions of
interest were defined on resliced LV short-axis
(summed)18FDG images and subsequently projected
onto the dynamic images. The regions of interest were
drawn as previously described [23] and grouped for
further analysis. Additional regions of interest were
defined in left and right ventricular chambers for H2
15O
image-derived input functions. A separate aorta ascen-
dence region of interest was defined for18FDG image-
derived input functions. Myocardial blood flow was
determined with the standard single-tissue compartment
model [24]. MMRglu was calculated by multiplying the
net influx constant for18FDG, Ki, by the mean plasma
glucose concentration. For determining of Ki, Patlak gra-
phic analysis was used [25].
Biochemical analyses
Fasting plasma OPG was measured using a sandwich
enzyme-linked immunosorbent assay and commercially
available antibodies (R&D Systems, Minneapolis, MN,
USA). The range of the assay was 62.5-4000 ng/L. The
intra-assay coefficient of variation was 3.5% [26]. Fasting
plasma ADPN was measured using a time-resolved
immunofluorometric assay based on two monoclonal
antibodies and recombinant human adiponectin (R&D
Systems, Abingdon, UK). The intra-assay coefficient of
variation was <5%, and the interassay coefficient of var-
iation was <10% [26,27]. N-terminal-pro-B-type
natriuretic peptide (NT-pro-BNP) was measured using
an electrochemiluminescence immunoassay (Roche
Diagnostics GmbH, Mannheim, Germany). The intra-
assay coefficient of variation was 1.5%, and the inter-
assay coefficient of variation was 1.9%.
Statistical analysis
Data are expressed as means ± standard deviations for
normally distributed data, or otherwise the median
(interquartile range) is used. T-tests or Mann-Whitney
U tests were used to determine group differences. Cor-
relation coefficients were calculated using the Pearson’s
product moment correlation. OPG and ADPN were
log-transformed for correlation and multivariable
regression analyses as both markers were non-normally
distributed. Linearity of the regression models was
judged based on histograms and scatterplots. As no
interactions were found between group and dependent
variables, both groups were analyzed as one for regres-
sion analysis. Additional potential confounders were
investigated by adding age, group status, HbA1c, NT-
pro-BNP, and blood pressure for associations of OPG
and age, group status, HDL-cholesterol, whole-body
insulin sensitivity (M-value), HbA1c, BMI, and waist
for association of ADPN one by one to the crude mod-
els. Variables that changed the regression coefficients
by more than 10% were included in the adjusted
model. Statistical analyses were performed using SPSS
Software (version 15.0, SPSS Inc., Chicago, IL, USA).
Values of P < 0.05 were considered statistically
significant.
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Results
As expected, T2DM patients versus healthy men had
increased BMI, waist, and HbA1c values, but lower HDL-
cholesterol, and M-value. Although within the normal
range, systolic and diastolic blood pressure and heart rate
were significantly higher in T2DM patients relative to
controls (Table 1). T2DM patients had a lower aortic dis-
tensibility as compared to controls. Furthermore, T2DM
patients and controls had comparable LV mass and sys-
tolic function parameters. Parameters related to LV
volume and diastolic function were, however, signifi-
cantly decreased in patients (Table 2). Insulin stimulated
MMRglu was significantly impaired in patients compared
with controls, in the presence of comparable myocardial
blood flow [2,17] (Table 2).
Plasma OPG levels were significantly elevated in
T2DM men compared to controls (Figure 1A), whereas
ADPN levels were lower (Figure 1B). PET examina-
tions were successful in 58 T2DM patients and 9 con-
trols. In T2DM patients, plasma OPG levels correlated
inversely with aortic distensibility, LV endsystolic
volume, E/A peak ratio and MMRglu, and positively
with age, and HbA1c and LV mass/volume ratio. The
correlations of plasma OPG with systolic blood pres-
sure and LV enddiastolic volume were only significant
in pooled analyses (Table 3). In multivariable regres-
sion analysis, plasma OPG was negatively associated
with aortic distensibility, even after adjustment for sys-
tolic blood pressure and age (b = -0.268, P = 0.007;
Figure 2A). Likewise, the association of plasma OPG
and LV mass/volume ratio was independent of systolic
blood pressure and age (b = 0.216, P = 0.05; Figure
2B). However, age and blood pressure significantly
affected the association between OPG and LV enddias-
tolic volume in the T2DM patients (b = -0.104, P =
0.32). In addition, age and HbA1c were contributors of
the association between OPG and E/A peak ratio (b =
-0.071, P = 0.47; Figure 2C).
Plasma ADPN levels were inversely correlated with
BMI and waist, and positively with HDL-cholesterol
and M-value, in T2DM patients. Correlations of ADPN
and HbA1c, rate pressure product and MMRglu were
only significant in pooled analyses. ADPN was not sig-
nificantly correlated with LV functional parameters
(Table 4). In multiple regression analysis, M-value,
HbA1c and waist were contributors of the association
between ADPN and MMRglu (b = 0.055, P = 0.66;
Figure 3).
Discussion
The present study confirmed the previously reported
increase in circulating OPG and decrease in ADPN
in patients with T2DM versus health controls. We
Table 1 Clinical and biochemical characteristics of study
subjects
T2DM
(n = 78)
Controls
(n = 14)
P value
Age (years) 56.5 ± 5.6* 54.5 ± 7.1 0.14
BMI (kg/m2) 28.7 ± 3.5* 27.4 ± 2.3 0.04
Waist (cm) 104.4 ± 10.2* 99.2 ± 8.9 0.03
Heart rate (beats/min) 61.7 ± 8.6 54.0 ± 7.8 0.004
Systolic blood pressure (mmHg) 130 ± 12* 121 ± 8 0.002
Diastolic blood pressure (mmHg) 82 ± 8 * 74 ± 7 < 0.001
Antihypertensive medication (%) 44* NA
Lipid lowering medication (%) 49* NA
Fasting plasma glucose (mmol/L) 8.3 (7.1-10.0)* 5.3 (5.1-5.5) < 0.001
Fasting insulin (pmol/L) 64 (36-92)* 29 (19-32) 0.001
HbA1c (%) 7.1 ± 1.0* 5.3 ± 0.2 < 0.001
Total cholesterol (mmol/L) 4.7 ± 1.0* 5.3 ± 0.7 0.01
HDL-cholesterol (mmol/L) 1.1 (0.9-1.3)* 1.4 (1.3-1.6) < 0.001
NT-proBNP (ng/L) 27 (20-42)* 28 (21-76) 0.26
M-Value (mg/kg min) 2.7 (1.6-4.2) 6.7 (4.3-8.1) < 0.001
*Adapted from Rijzewijk et al. [2]. Data are represented as means ± SD or as
median (interquartile range). BMI,: body mass index; NA: not applicable;
HbA1c: glycated hemoglobin; HDL: high-density lipoprotein; M-value: whole-
body insulin sensitivity; NT-pro-BNP: N-terminal-pro-B-type natriuretic peptide.
Table 2 Cardiac dimensions, function and glucose
metabolism
T2DM
(n = 78)
Controls
(n = 14)
P
value
Rate pressure product ((beats/min)
mmHg)
8503 ±
1458
7096 ±
1531
0.005
Distensibility aorta ascendens
(10-3mmHg-1)
3.13
(2.29-5.95)
5.63
(4.50-8.07)
0.008
LV mass (g) 107.3 ±
16.7*
111.7 ±
24.4
0.42
LV enddiastolic volume (mL) 154
(134-174)
180
(159-210)
0.002
LV end-systolic volume (mL) 59 (52-71)* 72 (63-82) 0.001
LV mass/volume ratio (g/mL) 0.70 ± 0.11 0.63 ± 0.09 0.05
Stroke volume (mL) 94 ± 16* 107 ± 23 0.002
LV ejection fraction (%) 60 ± 6* 59 ± 4 0.35
E peak filling rate (mL/s) 417 ± 84* 503 ± 112 <
0.001
E deceleration peak (mL/s2 10-3) 3.40
(2.89-3.99)*
4.73
(3.11-5.19)
0.003
E/A peak ratio 1.04 ±
0.25*
1.26 ± 0.36 0.01
E/Ea 9.3 (7.0-
11.7)
8.7
(6.4-10.8)
0.34
MBF (mL/g/min) 0.84
(0.75-0.96)
0.88
(0.77-1.01)
0.8
MMRglu (nmol/mL/min) 257 ± 130 348 ± 154 0.02
*Adapted from Rijzewijk et al. [2]. Data are represented as means ± SD or as
median (interquartile range). LV: left ventricular; E/A: ratio of peak filling rates
of the early filling phase and arterial contraction; E/Ea: estimated LV filling
pressures; MBF: myocardial blood flow; MMRglu: myocardial metabolic rate of
glucose uptake.
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extended these data by showing inverse associations of
OPG and cardiac function as well as aortic distensibility,
whereas ADPN was positively related to cardiac
metabolism.
These correlations were seen both in pooled analyses
and the analyses of T2DM men separately, but not in
the analyses of the controls alone.
Higher levels of OPG have documented in T2DM
patients with asymptomatic coronary artery disease
[28,29], but at the same time also in experimental and
clinical heart failure, even in the absence of ischemic
cardiomyopathy. Similarly, in our population inducible
ischemia was excluded. OPG has been associated with
progression of atherosclerosis in symptomatic cardiovas-
cular disease. For example, in a population based cohort,
serum OPG was significantly associated with myocardial
infarction, ischemic stroke, and total mortality [30].
Although, some indicate a beneficial role of OPG [8,31],
the higher levels of OPG have been interpreted as a
counter regulatory protective response to atherosclero-
sis. For instance, selective deletion of OPG in mice
results in significant medial calcification of the aorta
and renal arteries [31]. Futhermore, Ueland et al. [8]
showed enhanced systemic expression of RANKL and
increased expression of the receptor RANK in cardio-
myocytes, vascular smooth muscle cells and endothelial
cells of the failing myocardium. OPG can act as a decoy
receptor, binding to RANKL, preventing the interaction
of RANK and RANKL. Thereby, OPG can potentially
protect against the negative effects of RANKL. Besides,
in patients with subclinical atherosclerosis serum OPG
levels decreased linearly with increased calcification
expressed as an increased echogenicity of the athero-
sclerotic plaques [32]. In addition to LV diastolic func-
tion, in our study, plasma levels OPG were significantly
associated with age and HbA1c in T2DM patients,
showing close correlation between OPG and several car-
diovascular risk factors, as demonstrated previously
[10,33]. This is the first study showing an inverse asso-
ciation between OPG levels and arterial- and LV diasto-
lic function in asymptomatic T2DM patients in the
absence of inducible myocardial ischemia. The multi-
variate analysis indicated that plasma OPG may contri-
bute to the effect of aging and hyperglycemia on
arterial- and LV diastolic function in T2DM. These
results indicate a positive relationship between OPG and
cardiovascular disease, instead of a protective role of
OPG in cardiovascular disease.
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Figure 1 Plasma levels of osteoprotegerin (OPG) and
adiponectin (ADPN) of type 2 diabetic (T2DM) men (hatched
bar) and normoglycemic healthy controls (white bar). Bars
represent median (interquartile range). * P < 0.05.
Table 3 Correlations between osteoprotegerin and
clinical and biochemical characteristics, and cardiac
dimensions, function, and myocardial metabolism
Pooled
analysis
T2DM Controls
Age (years) 0.217* 0.343* -0.354
BMI (kg/m2) 0.054 0.050 -0.180
Systolic blood pressure (mmHg) 0.232* 0.181 0.297
Diastolic blood pressure (mmHg) 0.194 0.180 0.192
HbA1c (%) 0.325* 0.249* 0.312
Rate pressure product ((beats/min)
mmHg)
0.200 0.114 0.319
Log distensibility aorta ascendens (10-
3mm Hg-1)
-0.401* -0.327* -0.623*
LV mass (g) 0.034 0.096 -0.180
LV mass/volume ratio (g/mL) 0.277* 0.311* -0.164
Log LV enddiastolic volume (mL) -0.213* -0.211 -0.044
Log LV endsystolic volume (mL) -0.269* -0.248* -0.116
LV ejection fraction (%) 0.199 0.161 0.343
E peak filling rate (mL/s) -0.190 -0.193 -0.022
Log E deceleration peak (mL/s210-3) -0.167 -0.156 -0.083
E/A peak ratio -0.223* -0.272* -0.095
MMRglu (nmol/mL/min) -0.308* -0.307* -0.055
Data are Pearson’s r. BMI: body mass index; HbA1c: glycated hemoglobin; LV:
left ventricular; E/A: ratio of peak filling rates of the early filling phase and
arterial contraction; MMRglu: myocardial metabolic rate of glucose uptake.
* P < 0.05.
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The association between ADPN and systemic glucose
metabolism has been documented before by others
[12,13]. In the present study, we found a positive asso-
ciation of ADPN and myocardial glucose metabolism,
but not with cardiac function. This finding seems to be
at odds with previous data, which have described an
association of circulating levels of ADPN with para-
meters of cardiac structure and function in healthy
adults [34], elderly [35] and patients with coronary
artery disease and/or heart failure [36,37]. In addition,
in healthy subjects, circulating ADPN levels were inver-
sely related to LV wall thickness and mass [34] and, in
patients with coronary artery disease and/or heart
failure, they were positively related to NT-proBNP and
LV systolic dysfunction [36,37]. In chronic heart failure,
the paradoxical (positive) association of ADPN and car-
diac function was ascribed to its role in wasting in car-
diac cachexia [38]. Differences in study population, and
in methodology used to assess cardiac function and
ADPN analysis, respectively, all could have accounted
for the differential findings. Indeed, we studied men
with well-controlled uncomplicated T2DM and with
stress-echocardiography confirmed absence of inducible
ischemia, whereas others included healthy adults [34],
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Figure 2 Scatterplots with fitted regression curves (unadjusted)
of Log osteoprotegerin (OPG) and Log aortic distensibility, Log
OPG and left ventricular (LV) mass/volume ratio, and Log OPG
and E/A peak ratio, for all subjects.
Table 4 Correlations between adiponectin and clinical
and biochemical characteristics, and cardiac dimensions,
function, and myocardial metabolism
Pooled
analysis
T2DM Controls
Age (years) -0.070 -0.054 0.037
BMI (kg/m2) -0.224* -0.299* 0.495
Waist (cm) -0.284* -0.314* 0.153
Systolic blood pressure (mmHg) -0.123 -0.070 0.644
Diastolic blood pressure (mmHg) 0.038 0.180 0.083
HbA1c (%) -0.253* -0.095 -0.616*
Log HDL-cholesterol (mmol/liter) 0.414* 0.397* 0.192
Log M-Value (mg/kg min) 0.514* 0.485* -0.130
Rate pressure product ((beats/min)
mmHg)
-0.364* -0.270 -0.537
LV mass (g) -0.015 -0.004 0.083
LV ejection fraction (%) 0.051 0.112 -0.338
E peak filling rate (mL/s) 0.146 0.082 0.179
Log E deceleration peak (mL/s210-3) 0.091 0.073 -0.035
E/A peak ratio -0.027 -0.054 -0.018
MMRglu (nmol/mL/min) 0.288* 0.251 -0.066
Data are Pearson’s r. BMI: body mass index; HbA1c: glycated hemoglobin;
HDL: high-density lipoprotein; M-value: whole-body insulin sensitivity; LV: left
ventricular; E/A: ratio of peak filling rates of the early filling phase and arterial
contraction; MMRglu: myocardial metabolic rate of glucose uptake.
* P < 0.05.
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Figure 3 Scatterplot with fitted regression curves (unadjusted)
of Log adiponectin (ADPN) and myocardial metabolic rate of
glucose uptake (MMRglu) for all subjects.
Chen et al. Cardiovascular Diabetology 2011, 10:67
http://www.cardiab.com/content/10/1/67
Page 6 of 8
elderly [35] and patients with coronary artery disease
and/or heart failure [36,37].
Although in line with previous investigations, we have
determined total circulating ADPN levels in our study,
but other data suggest that high-molecular weight
ADPN may have stronger associations with insulin resis-
tance and coronary heart disease in T2DM patients [39].
Limitations of this study include the cross-sectional
design, which precludes conferring a causal relationship
between OPG, ADPN and the cardiac variables studied.
Furthermore, the correlations of OPG with cardiac func-
tion and ADPN with myocardial glucose uptake were
not observed in the healthy controls alone. This may be
due to the relatively small number of a homogeneous
control population.
In addition, the inclusion of only males with uncom-
plicated T2DM limits generalizations. On the other
hand, a strength of this investigation is the use of state-
of-the-art cardiac phenotyping methods in a relatively
large group of well-characterized T2DM patients.
Conclusions
The findings of this study indicate that in asymptomatic
men with uncomplicated T2DM, but without inducible
ischemia, OPG and ADPN may be markers of underly-
ing mechanisms linking the diabetic state to cardiac
abnormalities. The use of OPG and ADPN as markers
might add to the risk stratification of (future) cardiac
disease in asymptomatic men with less-advanced T2DM
prior to the onset of coronary artery disease.
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